Oral decitabine/cedazuridine is an effective ambulatory therapy for patients with myelofibrosis refractory to JAK2 inhibitor therapy
Article in Clinical Lymphoma Myeloma & Leukemia (May 2024)
The most recent citing publications are shown below. View all 98 publications that cite this research output on Dimensions.
Article in Clinical Lymphoma Myeloma & Leukemia (May 2024)
Article in Expert Opinion on Pharmacotherapy (April 2024)
Article in Annals of Hematology (March 2024)